Hydroxychloroquine shows promise for reducing some of the debilitating systems associated with primary progressive multiple sclerosis, a new study reports. A University of Calgary study…
View More Hydroxychloroquine Delays Disability for Least Treatable Form of Multiple Sclerosis
Exercise is an effective therapeutic strategy for fatigue in patients with multiple sclerosis (MS), and combined exercise is the most effective modality for physical and…
View More Exercise Therapy Has Positive Effect on Multiple Sclerosis-Related Fatigue
The following article is part of conference coverage from the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held October 25-28 2021, in…
View More Long-Term Satralizumab Safe in Patients with Neuromyelitis Optica Spectrum Disorder
The following article is part of conference coverage from the 2021 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC), held October 25-28 2021, in…
View More Updated Guidelines on the Role of MRI in Multiple Sclerosis
Ocrelizumab, a humanized anti-CD20 immunoglobulin G (IgG) antibody, may effectively control the risk of relapse and disability worsening in patients with multiple sclerosis (MS), according…
View More Ocrelizumab Beneficial for Relapse Risk and Disability in Multiple Sclerosis
Patients with multiple sclerosis (MS) and SARS-CoV-2 were at increased risk for severe disease and mortality if they were of advanced age and had progressive…
View More SARS-CoV-2 Severity, Outcomes Linked to Age and Multiple Sclerosis Subtype
The 2021 Magnetic Resonance Imaging in Multiple Sclerosis (MAGNIMS), Consortium of Multiple Sclerosis Centres (CMSC), North American Imaging in Multiple Sclerosis Cooperative (NAIMS), provided updated…
View More The Changing Guidelines on the Role of MRI in Multiple Sclerosis Management
To date, there has yet to be established clear clinical, imaging, pathological, or immunological criteria to mark the transition from relapse-remitting multiple sclerosis (RRMS) to…
View More Emerging Research Provides Insight in Secondary Progressive MS
New results indicate that early intensive treatment (EIT) strategy is more effective than escalation to higher-efficacy disease-modifying therapy (ESC) strategy in controlling disability progression over…
View More The early intensive treatment strategy is more effective than escalation treatment in MS patients to controlling disability progression